Pharmaxis Ltd (AU:SNT) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Syntara Limited’s interim results from its Phase 2 trial for the myelofibrosis treatment SNT-5055, in combination with ruxolitinib, will be showcased in an oral presentation at the upcoming American Society of Hematology meeting. This recognition highlights the promise of SNT-5055, which has shown encouraging results in tackling bone marrow cancer. Syntara is advancing multiple clinical studies targeting high unmet medical needs, positioning itself as a key player in innovative blood cancer treatments.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
